Imugene Limited (ASX:IMU) Granted FDA Fast Track Designation for Azer-cel
Imugene Limited (ASX:IMU) secures FDA Fast Track designation for its allogeneic CAR T-cell therapy azer-cel, advancing treatment for relapsed or refractory diffuse large B-cell lymphoma.